Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 8, 2012

View Archived Issues

NeoGenomics launches prognostic cancer test in U.S.

Discovery of a novel mineralocorticoid receptor antagonist

Proteome Sciences provides CKI-delta inhibitor portfolio update

Foundation Medicine and Clovis Oncology launch collaboration

Aquapharm discovers antibiotic against multidrug-resistant bacteria

Antisense products show promise in model of myotonic dystrophy

Fate Therapeutics divulges novel Wnt compositions

ACEA Biosciences presents new candidate cancer therapeutics

In vivo studies demonstrate neuroprotective effects of microRNA's silencing

Crystal Biopharmaceutical patents novel camptothecin derivatives

New anticancer microRNA prepared in the Netherlands

Ono Pharmaceutical announces highlights of second quarter 2012

Researchers at Lilly disclose novel kinase inhibitors

Shire reviews accomplishments for second quarter of 2012

Astellas files for approval of orally disintegrating tablet for IBS

NeurogesX provides update on next steps for NGX-1998

Trana identifies new target for development of antibiotics

Antibody targeting Wnt/beta-catenin pathway shows promising anticancer activity

Affinium completes enrollment in phase II trial of oral antibiotic for ABSSSI

New cancer vaccines designed by Oncbiomune

Mylan out-licenses Japanese rights to next-generation epinephrine product

Novel immune deficiency and immune dysregulation phenotype and related gene mutation identified

Recruitment complete in study of rheumatoid arthritis stem cell therapy

Achillion provides update on candidate drugs for genotype 1 HCV infection

AstraZeneca to halt development of CytoFab

OncoGenex kicks off enrollment in AFFINITY study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...